15th Sep 2008 10:46
AGI Therapeutics plc
Director Share Dealing
Dublin, Ireland, 15 September 2008 - AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a specialty pharmaceutical company focused on gastrointestinal drug products, announces that the Company was informed on the 12 September 2008 that Dr. Chris Blackwell, a Non-Executive Director of the Company has purchased 15,000 ordinary shares of €0.01 each in the share capital of the Company at a price of €0.86 each.
Following the transaction, Dr Blackwell is the beneficial owner of 15,000 ordinary shares, representing approximately 0.02% of the Company's current issued share capital.
For further information, please contact:
|
AGI Therapeutics plc. |
Tel: +353 1 449 3254 |
|
David Kelly, Chief Financial Officer |
|
|
Piper Jaffray Limited |
Tel: +44 (0) 20 3142 8700 |
|
Neil Mackison |
|
|
Will Carnwath |
About AGI Therapeutics plc
AGI is a speciality pharmaceutical company which is focused on the development and commercialisation of differentiated drug products for gastro-intestinal (GI) diseases and disorders. AGI's common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.
The Company has a portfolio of product candidates derived from its Known Molecular Entity (KME) approach to drug re-profiling and development. The Company's lead product candidate, RezularTM, is an orally administered triple-action intestinal regulator, a first-in-class mechanism for the treatment of diarrhoea predominant Irritable Bowel Syndrome (IBS-D).
KME is a re-profiling methodology used by the Company to identify existing therapeutic drugs which typically have been marketed for a number of years, have established safety profiles and can be developed for new clinical indications or with improved profiles in their existing clinical indications. In this way, the Company seeks to reduce the risk, time and cost of new product development as compared to the development of new chemical entities.
AGI is developing a range of product candidates to treat a variety of prevalent GI diseases and disorders, including irritable bowel syndrome (IBS), dyspeptic symptoms, gastroparesis, ulcerative colitis, gastro-esophageal reflux disease (GERD) and diarrhoea-related conditions such as chemotherapy-induced diarrhoea (CID). The Company is targeting areas of the GI therapeutic drug products market for its product candidates where there are currently unmet medical needs or where the effectiveness of existing drug therapies can be further improved.
The Company has five active clinical stage product candidates which are either isomers or new drug delivery formulations of existing approved drugs and which have established safety and tolerability profiles in their currently approved clinical indications.
For further information please see www.agitherapeutics.com
Related Shares:
Potentially Ai